J
Jasna Kriz
Researcher at McGill University Health Centre
Publications - 5
Citations - 620
Jasna Kriz is an academic researcher from McGill University Health Centre. The author has contributed to research in topics: Amyotrophic lateral sclerosis & Neurodegeneration. The author has an hindex of 5, co-authored 5 publications receiving 604 citations.
Papers
More filters
Journal ArticleDOI
Minocycline Slows Disease Progression in a Mouse Model of Amyotrophic Lateral Sclerosis
TL;DR: Results indicate that minocycline, which is clinically well tolerated, may represent a novel and effective drug for treatment of ALS.
Journal ArticleDOI
Efficient three‐drug cocktail for disease induced by mutant superoxide dismutase
TL;DR: Results indicate that a combination approach consisting of three drugs for distinct targets in the complex pathway to neuronal death, minocycline, riluzole, and nimodipine may represent an effective strategy for ALS treatment.
Journal ArticleDOI
Pathways to motor neuron degeneration in transgenic mouse models.
TL;DR: The analysis of transgenic mice expressing mutant SOD1 has yielded complex results, suggesting that multiple pathways may contribute to disease that include the involvement of non-neuronal cells.
Patent
Therapy for stroke
Jean-Pierre Julien,Jasna Kriz +1 more
TL;DR: In this paper, a method for reducing symptoms related to stroke, this therapy comprising the administration of a therapeutically effective amount of at least two compounds selected from the group of an inhibitor of microglial activation, an antiglutaminergic agent and a voltage gated calcium channel blocker to a patient suffering from a neurodegenerative disease.
Patent
Therapy for neurodegenerative diseases
Jean-Pierre Julien,Jasna Kriz +1 more
TL;DR: In this paper, the authors proposed a method for reducing symptoms related to a neurodegenerative disease and/or treating a neuro degenerative disease, this therapy comprising the administration of a therapeutically effective amount of at least two compounds selected from the group of an inhibitor of microglial activation, an antiglutaminergic agent and a voltage gated calcium channel blocker in association with a pharmaceutically acceptable carrier.